Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 2/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8975220 | 1.00 | CYP2A6 (0.61) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL8975209 | 1.00 | CYP2A6 (0.61) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL4958248 | 0.95 | TDP1 (0.62) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL22229849 | 0.89 | CHRNA7 (0.58) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL7474917 | 0.89 | CHRNA7 (0.58) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL9519417 | 0.87 | CYP2A6 (0.57) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL9519412 | 0.87 | CYP2A6 (0.57) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL12197971 | 0.86 | TDP1 (0.62) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| SCHEMBL3927981 | 0.86 | CYP2A6 (0.65) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 | |
| Bromide SCHEMBL18838899 | 0.84 | TDP1 (0.61) | CYP2A6TDP1L3MBTL1HRH1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9551018-B2 | Process for the preparation of optically active chiral amines | LONZA AG (CH) | 2017-01-24 | — | — | US | claimed |
| US-20150284752-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CHIRAL AMINES | LONZA AG (CH) | 2015-10-08 | — | — | US | claimed |
| US-9074228-B2 | Process for the preparation of optically active chiral amines | LONZA AG (CH) | 2015-07-07 | — | — | US | claimed |
| CN-101384723-B | Process for the preparation of optically active chiral amines | LONZA AG | 2013-03-27 | — | — | CN | claimed |
| EP-2202318-A1 | Process for the preparation of optically active chiral amines | Lonza AG (CH) | 2010-06-30 | — | — | EP | claimed |
| EP-1987152-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CHIRAL AMINES | LONZA AG (CH) | 2010-05-26 | — | — | EP | claimed |
| US-20090246837-A1 | Process for The Preparation of Optically Active Chiral Amines | LONZA AG (CH) | 2009-10-01 | — | — | US | claimed |
| CN-101384723-A | Process for the preparation of optically active chiral amines | LONZA AG (CH) | 2009-03-11 | — | — | CN | claimed |
| EP-1987152-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CHIRAL AMINES | Lonza AG (CH) | 2008-11-05 | — | — | EP | claimed |
| EP-1897956-A1 | Process for preparation of optically active amines by optical resolution of racemic amines employing a bacterial omega-transaminase | Lonza AG (CH) | 2008-03-12 | — | — | EP | claimed |
| WO-2007093372-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CHIRAL AMINES | LONZA AG (CH) | 2007-08-23 | — | — | WO | claimed |
| EP-1818411-A1 | Process for the preparation of optically active chiral amines | Lonza AG (CH) | 2007-08-15 | — | — | EP | claimed |
| US-20020032206-A1 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders | CALDWELL WILLIAM SCOTT (US) | 2002-03-14 | — | — | US | claimed |
| EP-0900200-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-03-10 | — | — | EP | claimed |
| WO-1997040011-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R. J. REYNOLDS TOBACCO COMPANY (US) | 1997-10-30 | — | — | WO | claimed |
| EP-2202317-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CHIRAL AMINOPYRROLIDINES (3-AP, B3-AP) | LONZA AG (CH) | 2017-03-01 | — | — | EP | disclosed |
| US-9551018-B2 | Process for the preparation of optically active chiral amines | LONZA AG (CH) | 2017-01-24 | — | — | US | disclosed |
| EP-0298466-A2 | Substituted alkene carboxylic acid amides and derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-01-11 | — | — | EP | disclosed |
| US-4788206-A | CARDIOVASCULAR DISORDERS, PLATELETS | HOFFMANN-LA ROCHE INC. (US) | 1988-11-29 | — | — | US | disclosed |
| US-4786646-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | HOFFMANN-LA ROCHE INC. (US) | 1988-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032206-A1 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders | PMP22, AANAT, CHAT | CYP2A6 172/4885TDP1 1227/4885L3MBTL1 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.